Dishman Carbogen Amcis Ltd

- No explicit mention of any current or planned new fundraising through debt or equity in the transcript. - Net debt as of June 30, 2024, stood at CHF 164 million, with no direct commentary on raising new debt. - The company expects to keep CAPEX largely maintenance-focused without significant growth CAPEX, which suggests no immediate large funding needs. - There is no indication from management about equity fundraising or debt refinancing plans in the Q&A. - Financial strategy seems to focus on improving operating performance and cash flow to manage existing obligations rather than new funding rounds.

- No significant growth CAPEX is expected in the near future. - CAPEX will mainly focus on maintenance and compliance to ensure GMP compliance. - Maintenance CAPEX is estimated to be around Rs. 17-18 crores annually. - Recent investments include a new French facility worth about €50 million, which has just started generating revenue and is currently underutilized. - Potential for revenue increase exists across various group facilities without requiring major new CAPEX. - Strategic focus is on improving utilization and operational efficiency rather than large new capital investment.

- India CRAMS business expected to grow significantly post regulatory clearance, targeting Rs. 325-350 crores revenue for FY 2025, with further growth in subsequent years closer to Rs. 400 crores. - Swiss entity anticipated to deliver growth year-over-year on both development and commercial fronts; aiming to exceed CHF 200 million revenue for FY 2025. - Overseas entities (Swiss, Dutch, Shanghai, Manchester) have capacity to improve utilization and revenues. - French facility, recently started, currently unutilized; expected to ramp up and reduce losses by Q3 FY 2025. - Overall group expects about 10% incremental revenue growth over last year. - Potential positive impact from global pharma shifts (e.g., sourcing away from China) benefiting European and Indian operations. - Maintenance CAPEX expected around Rs. 17-18 million annually; no major growth CAPEX anticipated.

- The company targets about 10% top-line growth for the current financial year with potential upside depending on Q2 and Q3 performance. - EBITDA margin is expected to improve to approximately 18% for FY25, higher than last year due to reduced goodwill write-offs and operational improvements. - Q2 is anticipated to return to the 18% EBITDA margin run rate, supporting annual targets. - The India CRAMS business is projected to grow from Rs. 250 crores to Rs. 325-350 crores revenue in FY25, with further upside expected in subsequent years. - Europe entities, especially Swiss and Dutch, foresee modest single-digit growth in revenues, recovering from cost pressures. - Overall, operating profits should be significantly higher than last year, with positive profit after tax likely in the current financial year. - The company does not expect major CAPEX, focusing on maintenance and compliance, which supports improving returns.

- The company has a large product portfolio of orders to process in the coming months, especially at the new drug product facility in France and the Swiss facility. - There is noticeable traction and increasing orders from existing and new customers at the India site following regulatory clearances. - The Swiss entity has a strong orderbook across drug substance, drug product, and specialty segments, supporting confidence in meeting annual targets despite Q3 disappointments. - Globally, there is a substantial number of purchase orders in the pipeline, with positive demand from pharma and non-pharma markets (cosmetics). - Collaborative efforts are ongoing between Swiss and Bavla (India) sites to transfer projects and increase order fulfillment capacity. - Management remains optimistic about orderbook growth and achieving stronger financial performance for the full year.